General Electric Co.'s (GE) spinout of its Healthcare business in an IPO has been a highly anticipated med-tech industry event for 2019. But now all that is back into play. The Boston-based conglomerate has opted to sell its Biopharma business for $21.4 billion to Danaher Corp. That Biopharma unit accounted for about 15 percent, or about $3 billion, of the almost $20 billion in 2018 Healthcare revenues.